Choriocarcinoma

Choriocarcinoma is a highly malignant form of gestational trophoblastic neoplasia characterized by aggressive trophoblastic proliferation and early hematogenous spread. It may occur following a hydatidiform mole, spontaneous abortion, ectopic pregnancy, or term pregnancy. Despite its aggressive nature, choriocarcinoma is one of the most chemotherapy-sensitive malignancies, and cure is possible even in the presence of metastatic disease. All patients require careful pretreatment evaluation for staging and risk stratification to guide treatment.

Epidemiology

Choriocarcinoma is a rare trophoblastic malignancy that occurs in women of reproductive age. It may develop after any type of pregnancy but is most commonly associated with antecedent molar pregnancy. Early diagnosis and appropriate risk-based chemotherapy have resulted in excellent survival rates.

Risk factors

Risk factors include:

• Previous hydatidiform mole.

• Previous gestational trophoblastic disease.

• History of spontaneous abortion.

• Previous ectopic pregnancy.

• Previous term pregnancy associated with trophoblastic disease.

• Persistently elevated β-hCG following pregnancy.

Pathophysiology

Choriocarcinoma arises from malignant transformation of trophoblastic tissue. The tumor consists of proliferating cytotrophoblasts and syncytiotrophoblasts without the formation of chorionic villi. It produces large amounts of β-human chorionic gonadotropin (β-hCG), which serves as an important diagnostic and monitoring marker.

The disease spreads primarily through the bloodstream and commonly metastasizes to:

• Lungs.

• Vagina.

• Pelvis.

• Liver.

• Brain.

• Gastrointestinal tract.

• Kidneys.

Because of its marked sensitivity to chemotherapy, even metastatic disease may be curable when appropriately treated.

Clinical presentation

The most common presentation is persistent elevation or plateauing of serum β-hCG following a molar pregnancy or other antecedent pregnancy.

Patients may also present with symptoms related to metastatic disease depending on the organs involved.

Symptoms

Primary disease

• Persistently elevated β-hCG after pregnancy.

• Persistent or recurrent vaginal bleeding.

• Pelvic pain.

• Abnormal uterine bleeding.

Pulmonary metastases

• Cough.

• Hemoptysis.

• Shortness of breath.

• Chest pain.

Brain metastases

• Headache.

• Seizures.

• Altered consciousness.

• Focal neurological deficits.

Liver metastases

• Right upper quadrant pain.

• Hepatomegaly.

• Jaundice.

Advanced disease

• Weight loss.

• Fatigue.

• Symptoms related to metastatic spread.

Clinical signs

• Enlarged uterus.

• Vaginal lesions or nodules.

• Vaginal bleeding.

• Pulmonary signs associated with lung metastases.

• Neurological signs associated with brain metastases.

• Hepatomegaly in liver involvement.

• Signs of anemia due to chronic bleeding.

Differential diagnosis

Conditions that may present similarly include:

• Persistent hydatidiform mole.

• Invasive mole.

• Retained products of conception.

• Ectopic pregnancy.

• Miscarriage.

• Endometrial carcinoma.

• Cervical carcinoma.

• Other gestational trophoblastic neoplasms.

• Metastatic malignancies involving the uterus.

Diagnostic criteria

Choriocarcinoma should be suspected in patients with:

• Persistently rising β-hCG following molar pregnancy.

• Plateauing β-hCG following molar pregnancy.

• Elevated β-hCG associated with evidence of metastatic disease.

• Histological confirmation of choriocarcinoma.

Definitive diagnosis is established through clinical, biochemical, radiological, and histopathological evaluation.

Investigations

Laboratory investigations

• Serum β-hCG level.

• Liver function tests (LFTs).

• Renal function tests (RFTs).

• Thyroid stimulating hormone (TSH).

• Triiodothyronine (T3).

• Thyroxine (T4).

• Full blood count (FBC).

• Platelet count.

• Cerebrospinal fluid (CSF) hCG level when indicated.

Imaging investigations

• Chest X-ray (CXR).

• CT scan of the chest.

• Ultrasound of the abdomen and pelvis.

• CT scan of the abdomen and pelvis.

• Brain MRI.

• PET/CT.

Histopathological investigations

• Tissue sample for histological confirmation.

Diagnostic staging

FIGO Stage I

• Persistently elevated β-hCG.

• Tumor confined to the uterine corpus.

FIGO Stage II

• Tumor extends to the adnexa or vagina.

• Disease remains limited to genital structures.

FIGO Stage III

• Pulmonary metastases demonstrated on chest imaging.

• With or without uterine, pelvic, or vaginal involvement.

FIGO Stage IV

• Metastatic disease beyond the lungs, pelvis, or vagina.

Prognostic risk assessment (WHO/FIGO scoring system)

Risk assessment should include evaluation of:

• Age.

• Antecedent pregnancy.

• Interval from index pregnancy.

• Pretreatment β-hCG level.

• Largest tumor size.

• Site of metastasis.

• Number of metastases.

• Previous failed chemotherapy.

Low-risk disease

• FIGO Stage I–III.

• WHO risk score less than 7.

High-risk disease

• FIGO Stage IV.

• FIGO Stage II or III with WHO risk score 7 or greater.

Management

Management is determined by FIGO stage and WHO risk score.

Serial β-hCG monitoring is mandatory throughout treatment.

Non-pharmacological treatment

Monitoring

All patients should undergo:

• Serial β-hCG measurement at initiation of treatment.

• Weekly β-hCG measurement during therapy.

• Radiological assessment as clinically indicated.

• Long-term surveillance after completion of therapy.

Brain metastases

Patients with brain metastases may require:

• Whole-brain radiotherapy.

• Neurological monitoring.

• Seizure prevention measures.

Whole-brain radiotherapy

• 20–30 Gy.

• Delivered in 2 Gy daily fractions.

• Administered concurrently with high-dose chemotherapy.

Pharmacological treatment

Low-risk disease

Single-agent chemotherapy

Actinomycin D regimen

Actinomycin D

• 12 micrograms/kg intravenously daily for 5 days.

Response assessment:

• If response occurs, repeat the same dose.

If no response:

• Increase dose by 2 micrograms/kg from the initial dose.

Or

• Switch to methotrexate protocol.

Methotrexate regimen

Methotrexate

• 0.4 mg/kg intravenously or intramuscularly daily for 5 days.

Response assessment:

• If response occurs, repeat the same dose.

If no response:

• Increase dose by 0.6 mg/kg from the initial dose.

Or

• Switch to actinomycin D protocol.

High-risk disease

Combination chemotherapy

Recommended regimens include:

1. EMACO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine).

2. APE (actinomycin D, cisplatin, etoposide).

EMACO regimen

Course 1 (EMA)

Day 1

Etoposide (VP-16)

• 100 mg/m² intravenously over 30 minutes.

AND

Actinomycin D

• 0.5 mg intravenous bolus.

AND

Methotrexate

• 100 mg/m² intravenous bolus.

Followed by:

Methotrexate

• 200 mg/m² intravenous infusion over 12 hours.

Day 2

Etoposide (VP-16)

• 100 mg/m² intravenously in 200 mL normal saline over 30 minutes.

AND

Actinomycin D

• 0.5 mg intravenous bolus.

AND

Folinic acid

• 15 mg intramuscularly or orally every 12 hours for 4 doses.

• Begin 24 hours after initiation of methotrexate.

Course 2 (CO)

Day 8

Vincristine

• 1 mg/m² intravenous bolus.

AND

Cyclophosphamide

• 600 mg/m² intravenous infusion over 1 hour.

Duration of treatment

• Repeat cycles every 14 days.

• Continue until β-hCG becomes normal.

Management of brain metastases

One of the following approaches may be used:

• Methotrexate plus dexamethasone plus prophylactic antiepileptic therapy.

Or

• High-dose EMACO plus intrathecal methotrexate and leucovorin.

Concurrent treatment:

• Whole-brain radiotherapy 20–30 Gy in 2 Gy daily fractions.

Monitoring during chemotherapy

Perform:

• Weekly serum β-hCG.

• Daily full blood count (FBC).

• Daily platelet count.

• Daily liver function tests (LFTs).

If there is no response to single-agent chemotherapy:

• Escalate to combination chemotherapy.

Management according to underlying cause

Low-risk choriocarcinoma

• Single-agent methotrexate or actinomycin D.

High-risk choriocarcinoma

• Combination chemotherapy using EMACO or APE regimen.

Brain metastases

• High-dose chemotherapy.

• Intrathecal methotrexate and leucovorin where indicated.

• Dexamethasone.

• Prophylactic antiepileptic therapy.

• Whole-brain radiotherapy.

Referral

All patients with suspected or confirmed choriocarcinoma should be urgently referred to specialized cancer centers with expertise in gestational trophoblastic neoplasia.

Urgent referral is required for:

• Rising or plateauing β-hCG after molar pregnancy.

• Histologically confirmed choriocarcinoma.

• Metastatic disease.

• Brain metastases.

• Failure of initial chemotherapy.

Complications

• Massive hemorrhage.

• Pulmonary metastases.

• Brain metastases.

• Liver metastases.

• Neurological complications.

• Treatment-related toxicity.

• Disease recurrence.

• Death if untreated.

Prognosis

Choriocarcinoma has an excellent prognosis when diagnosed early and treated appropriately. Cure rates are extremely high because of the remarkable sensitivity of the disease to chemotherapy. Even patients with metastatic disease may achieve complete remission with appropriate risk-adapted treatment.

Prevention

• Early diagnosis and treatment of hydatidiform mole.

• Regular post-molar β-hCG surveillance.

• Prompt investigation of persistently elevated β-hCG.

• Adherence to follow-up protocols after molar pregnancy.

• Early referral of suspected gestational trophoblastic neoplasia.

Follow-up

During treatment

• Serial β-hCG measurement at treatment initiation.

• Weekly β-hCG measurements throughout therapy.

After treatment

• Weekly β-hCG measurements until normal for 3 consecutive weeks.

• Monthly β-hCG measurements until normal for 12 consecutive months.

Contraception

• Effective contraception should be maintained throughout the entire hormonal follow-up period.